Folate-conjugated rapamycin slows progression of polycystic kidney disease
about
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsExperimental therapies and ongoing clinical trials to slow down progression of ADPKDEffects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney DiseaseThe cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease.Molecular pathways and therapies in autosomal-dominant polycystic kidney diseaseMacrophage migration inhibitory factor promotes cyst growth in polycystic kidney diseaseThe Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor EverolimusBlocking rpS6 Phosphorylation Exacerbates Tsc1 Deletion-Induced Kidney GrowthA mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney diseaseNew treatments for autosomal dominant polycystic kidney diseaseAn emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.Diverse origins of the myofibroblast—implications for kidney fibrosis.Nephronophthisis: should we target cysts or fibrosis?Clinical Trials and a View Toward the Future of ADPKD.Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.Validation of Effective Therapeutic Targets for ADPKD Using Animal Models.Primary Cilia in Cystic Kidney Disease.Emerging Therapies for Childhood Polycystic Kidney Disease.Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.Hyperosmotic stress stimulates autophagy via polycystin-2.New Roles of the Primary Cilium in Autophagy.Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.Cellular senescence in the aging and diseased kidney.Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model.Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD.Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.
P2860
Q26823023-137A45B9-D742-4E46-BFC0-D30571784841Q27001230-25840864-5C4A-4BD5-948C-4B39854D0767Q27320627-F22F0F5B-EDA8-4229-B8C3-2DBE2CE48321Q33974670-FAC6022B-FD38-4CAD-B03B-CE1590E43877Q34074513-8D63BBC8-2DDB-4A53-B631-63DF91A220E3Q34634516-97B64902-A795-49E7-B9A3-4FBA383FE3C3Q34979740-9CD2BD1A-03B3-42DA-8565-B26DD767B34FQ35578646-CE639C8D-1F32-4670-A851-5CC0FB89B560Q35836161-F88DEB69-227B-4BF7-9BC6-0FFF2A3332DDQ36003176-4C516F48-9984-46C1-B90B-F7B747CDB7B2Q36307879-9BE4907F-FA13-419B-B777-9BE38A23F747Q36746057-AF84B4E5-EC41-46C7-99EF-57FB2556E275Q36810726-14F74374-259A-4C22-92AB-DC045E51C219Q38099698-DA008998-40CB-4BD5-83A8-37973C18AEAEQ38232593-59E90EA2-D6E0-49EC-8E4C-7A201108DB80Q38316792-16FFFF28-8C14-4237-A97F-11701677588DQ38556258-C6C99262-0CB4-440B-90F5-1DEA7D591CAFQ38812543-AB4E38C3-1E71-4930-9942-A0BEF7E71119Q38919283-4BCFCCD3-AFE0-4331-8DE1-03A740D0B8DEQ38978468-7E54183A-441B-49CD-B04C-066E7E2EBCA7Q39242476-BFEB26FF-C146-4CDF-B79D-B7A1F6341106Q39285003-54874946-9547-4D5E-8D52-2062521D9437Q41247634-1A5DA725-F9E3-4A06-A75B-A1B4270C2BB7Q41348260-F347DFC9-D9E1-4122-ACBD-81D6F0ABAC5EQ41621355-70E6735D-9DEF-44A8-824E-1AF2466570BEQ47742358-13C4937A-D790-40D8-B851-F8F5A51492D8Q48089331-2A83A355-9B34-4A0A-952E-E490846837EFQ51241436-E213279F-8422-4C6F-ABBD-997BA624109FQ52668626-3BF0F578-A2CD-4378-874A-D517A7AE5DC9Q54409988-2D548495-285B-4840-B4E7-111113298869
P2860
Folate-conjugated rapamycin slows progression of polycystic kidney disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@ast
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@en
type
label
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@ast
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@en
prefLabel
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@ast
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@en
P2093
P2860
P356
P1476
Folate-conjugated rapamycin slows progression of polycystic kidney disease
@en
P2093
Christopher P Leamon
Iontcho R Vlahov
Jonathan M Shillingford
Thomas Weimbs
P2860
P304
P356
10.1681/ASN.2012040367
P577
2012-08-02T00:00:00Z